In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Omega-3 PUFAs supplementation favorably affect left ventricle strain and the inflammatory, fibrosis process

Session Poster session 1

Speaker Evangelos Oikonomou

Event : ESC Congress 2016

  • Topic : basic science
  • Sub-topic : Basic Science - Cardiac Biology and Physiology
  • Session type : Poster Session

Authors : E Oikonomou (Athens,GR), D Karlis (Athens,GR), T Zografos (Athens,GR), G Siasos (Athens,GR), C Chrysohoou (Athens,GR), S Brili (Athens,GR), G Lazaros (Athens,GR), A Antonopoulos (Athens,GR), G Georgiopoulos (Athens,GR), G Vogiatzi (Athens,GR), P Nihoyannopoulos (Athens,GR), D Tousoulis (Athens,GR)

E. Oikonomou1 , D. Karlis1 , T. Zografos1 , G. Siasos1 , C. Chrysohoou1 , S. Brili1 , G. Lazaros1 , A. Antonopoulos1 , G. Georgiopoulos1 , G. Vogiatzi1 , P. Nihoyannopoulos1 , D. Tousoulis1 , 1Hippokration Hospital, University of Athens, 1st Department of Cardiology - Athens - Greece ,

European Heart Journal ( 2016 ) 37 ( Abstract Supplement ), 115-116

Background: Omega-3 polyunsaturated fatty acids (PUFAs) exert anti-inflammatory properties and have been tested in patients with systolic heart failure (HF). Soluble suppression of tumorigenicity 2 (sST2) has emerged as a novel biomarker for HF, is a member of the interleukin 1 (IL1) receptor family and is released from cardiomyocytes and fibroblasts after mechanical strain and has been identified as a novel biomarker of cardiac stress, fibrosis and remodeling. Moreover, serum levels of sST2 are associated with prognosis of HF patients.

Purpose: To examine the short term impact of omega-3 PUFAs on novel indices of left ventricle function and on the cardiac stress and fibrinogenesis process.

Methods: The study was carried out on two separate arms (omega-3 PUFAs-2gr/day- or placebo for 8 weeks), in a cross-over double blind design with an 8-wash out period between the two arms. The study population consisted of 17 systolic stable HF patients of ischemic etiology. All subjects were under optimal medical therapy for a period of 6 months. All subjects were evaluated at baseline and after completion of each treatment arm. Left ventricular (LV) function before and after treatment was assessed using LV ejection fraction (LVEF), determined by the biplane modified Simpson method, and LV global longitudinal strain (GLS), using a commercially available software. Serum levels of sST2 were measured at each examined day as a biomarker of inflammation, myocardial stress and fibrosis.

Results: Seventeen subjects (age 65.7±5.7yr) were included in the study. In the PUFA group a significant improvement in sST2 levels were observed at the end of the treatment period compare to pre-treatment levels [219 (161–362)ng/ml vs. 212 (158–315)ng/ml, p=0.006]. In the placebo group there was no improvement at the end of the treatment period compare to pre-treatment levels [215 (155–325)ng/ml vs. 211 (160–340)ng/ml, p=0.22]. Importantly, a significant improvement in LV function as assessed by LVEF and GLS was observed only after PUFA treatment (35.4±7.6% vs. 33.4±6.8%; p=0.032, and -11.6±3.3% vs. -10.1±2.9%; p=0.022, respectively) as well as a marginal improvement in LV diastolic and systolic dimensions (55.7±6.0mm vs. 57.1±6.2mm; p=0.245, and 45.1±6.7mm vs. 47.6±5.2mm; p=0.09, respectively). Interestingly, in the PUFA group there was as significant correlation between the improvement in sST2 levels and the improvement in GLS (rho=0.6, p=0.01) while there was no such correlation concerning the improvement in FMD and the LVEF.

Conclusions: In systolic HF patients, short term treatment with omega-3 PUFAs downregulates levels of sST2 with a parallel improvement in left ventricle ejection fraction and global longitudinal strain. These findings shed lights on the possible favorable mechanisms of omega-3 PUFAs in patients with ischemic heart failure.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are